Pre-Open Movers 11/09: (OTIC) (SAGE) (ROKU) Higher; (VSTO) (OPK) (EPC) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St stocks end higher with major corporate earnings in view
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
- Tesla expands price cuts to China, Germany after reducing FSD cost; shares down
- Gold prices slide as M.East fears ease, rate jitters persist
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Vista Outdoor (VSTO) PT Lowered to $14.50 at Cowen; Reiterates Market Perform
November 13, 2017 7:06 AM ESTCowen lowered its price target on Vista Outdoor (NYSE: VSTO) to $14.50 (from $26.00) while maintaining a Market Perform rating. Eroding ammo pricing trends may continue given diminished prospects for restrictive gun laws, oversupply, and new competition in certain calibers.
VSTO's 2Q adjusted EPS of $0.34 beat... More
Edgewell Personal Care (EPC) PT Lowered to $88 at RBC Capital Following 4Q
November 10, 2017 8:26 AM ESTRBC Capital lowered its price target on Edgewell Personal Care (NYSE: EPC) to $88.00 (from $105.00) while maintaining a Outperform rating following the company's 4Q earnings report. EPC disappointed on 4Q17 organic growth, EPS and guided FY18 EPS below consensus. Despite wet shave category challenges EPC... More
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy
November 10, 2017 8:16 AM ESTChardan Capital Markets upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price target of $140.00 following phase III Hummingbird data for brexanolone in PPD.
Analyst Gbola Amusa see a read-across from brexanolone in PPD to other vast-market indications, like MDD, Sage... More
Sage Therapeutics (SAGE) PT Raised to $105 at Stifel
November 9, 2017 12:43 PM ESTStifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $105.00 (from $91.00) while maintaining a Buy rating after the company reported positive top-line data from P3 Hummingbird trials with brexanolone (i.v. formulation) in postpartum depression (PPD).
Analyst Adam Walsh this... More
